CoChat

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

Open access
Pascual-Pasto, Guillem, Bazan-Peregrino, Miriam, Olaciregui, Nagore G., Restrepo-Perdomo, Camilo A., Mato-Berciano, Ana, Ottaviani, Daniela, Weber, Klaus, Correa, Genoveva, Paco, Sonia, Vila-Ubach, Monica, Cuadrado-Vilanova, Maria, Castillo-Ecija, Helena, Botteri, Gaia, Garcia-Gerique, Laura, Moreno-Gilabert, Helena, Gimenez-Alejandre, Marta, Alonso-Lopez, Patricia, Farrera-Sal, Marti, Torres-Manjon, Silvia, Ramos-Lozano, Dolores, Moreno, Rafael, Aerts, Isabelle, Doz, François, Cassoux, Nathalie, Chapeaublanc, Elodie, Torrebadell, Montserrat, Roldan, Monica, König, Andrés, Suñol, Mariona, Claverol, Joana, Lavarino, Cinzia, Carmen de, Torres, Fu, Ligia, Radvanyi, François, Munier, Francis L., Catalá-Mora, Jaume, Mora, Jaume, Alemany, Ramón, Cascalló, Manel, Chantada, Guillermo L., Carcaboso, Angel M. · 2019 · Science Translational Medicine

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aat9321

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Research works printed but not linked: 1

  1. 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J · DOI · Paper page

Cited by

See all 119

Metadata

Authors
Pascual-Pasto, G., Bazan-Peregrino, M., Olaciregui, N. G., Restrepo-Perdomo, C. A., Mato-Berciano, A., Ottaviani, D., Weber, K., Correa, G., Paco, S., Vila-Ubach, M., Cuadrado-Vilanova, M., Castillo-Ecija, H., Botteri, G., Garcia-Gerique, L., Moreno-Gilabert, H., Gimenez-Alejandre, M., Alonso-Lopez, P., Farrera-Sal, M., Torres-Manjon, S., Ramos-Lozano, D., Moreno, R., Aerts, I., Doz, F., Cassoux, N., Chapeaublanc, E., Torrebadell, M., Roldan, M., König, A., Suñol, M., Claverol, J., Lavarino, C., Carmen de, T., Fu, L., Radvanyi, F., Munier, F. L., Catalá-Mora, J., Mora, J., Alemany, R., Cascalló, M., Chantada, G. L., & Carcaboso, A. M.
Affiliations
  • Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
  • VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.
  • Hospital Sant Joan de Déu Barcelona (ES)
  • Pathology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
  • Centre National de la Recherche Scientifique (FR)
  • Chronobiotron (FR)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Vivotecnia Research S.L., Tres Cantos, Madrid 28760, Spain.
  • Pediatric Hematology-Oncology, Hospital Escuela Universitario, Tegucigalpa, Honduras.
  • Hôpital Ophtalmique Jules-Gonin (CH)
  • Ophthalmology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
Corresponding author
Carcaboso, Angel M.
Venue
Science Translational Medicine
Published
2019-01-23
Volume
11
Issue
476
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2911889173
Cited by
118
References
57
Citations by year
2026: 8 · 2025: 19 · 2024: 23 · 2023: 15 · 2022: 17 · 2021: 15 · 2020: 14 · 2019: 7
FWCI
7.99
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • IRIS (submittedVersion)
  • Conicet (submittedVersion, cc-by-nc-sa)
  • SERVAL (Université de Lausanne) (submittedVersion)
Funders
  • Seventh Framework Programme (PIRG-08-GA-2010-276998)
  • Institut national de la santé et de la recherche médicale (Cancer plan)
  • Fundación Científica Asociación Española Contra el Cáncer (Ayuda Retorno Investigadores)
  • Instituto de Salud Carlos III (CP13/00189)
  • Institut National Du Cancer
  • Ministerio de Economía, Industria y Competitividad, Gobierno de España (Cure4RB project RTC-2015-4319-1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
retinoblastoma, oncolytic adenovirus, E2F1, brain metastasis prevention, chemoresistance, vitreous inflammation, ocular survival
MeSH terms
Adenoviridae, Animals, Cytotoxicity, Immunologic, Humans, Neoplasm Metastasis, Rabbits, Retinoblastoma, Tissue Distribution, Virus Replication, Signal Transduction, Survival Analysis, Retinoblastoma Protein, Treatment Outcome, Xenograft Model Antitumor Assays, Cell Line, Tumor, Oncolytic Viruses, Mice, Translational Research, Biomedical, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. https://app.cochat.ai/papers/10.1126/scitranslmed.aat9321
The paper
Pascual-Pasto, G., Bazan-Peregrino, M., Olaciregui, N. G., Restrepo-Perdomo, C. A., Mato-Berciano, A., Ottaviani, D., Weber, K., Correa, G., Paco, S., Vila-Ubach, M., Cuadrado-Vilanova, M., Castillo-Ecija, H., Botteri, G., Garcia-Gerique, L., Moreno-Gilabert, H., Gimenez-Alejandre, M., Alonso-Lopez, P., Farrera-Sal, M., Torres-Manjon, S., . . . Carcaboso, A. M. (2019). Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aat9321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.